8-K: BioAtla CEO Gets Super-Voting Share Amid Reverse Split Struggle

BioAtla, Inc. issued a Super-Voting Share to its CEO, Jay M. Short, Ph.D., granting him significant voting power on specific proposals, including a pending reverse stock split, after failing to secure sufficient shareholder votes.

Summary

• BioAtla, Inc. authorized and issued one share of Series A Junior Preferred Stock (the Super-Voting Share) to its Chairman, CEO, and co-founder, Jay M. Short, Ph.D., for a purchase price of $0.01.
• The Super-Voting Share entitles the holder to vote together with common stockholders on specific 'Voting Proposals,' including amendments to reclassify common stock (e.g., reverse stock split) and related adjournments.
• The holder of the Super-Voting Share will cast votes equal to the total number of outstanding common shares on the record date for such proposals.
• The Super-Voting Share holder is required to vote all votes FOR a Voting Proposal if at least two-thirds (2/3) of the common stock present and entitled to vote approve it, and AGAINST if less than two-thirds (2/3) approve it.
• The Super-Voting Share does not entitle the holder to dividends, has a $0.01 liquidation preference, can be redeemed for $0.01, and cannot be transferred without Board consent.
• A Special Meeting of stockholders, originally convened on December 30, 2025, and reconvened on January 12, 2026, was held to vote on a Stock Issuance Proposal, a Reverse Stock Split Proposal (1-for-5 to 1-for-20 range), and an Adjournment Proposal.
• Stockholders approved the Stock Issuance Proposal and the Adjournment Proposal.
• The Reverse Stock Split Proposal failed to receive the required two-thirds (2/3) of the voting power of outstanding shares, despite over 70% of proxies received voting FOR it.
• The Special Meeting was adjourned again to January 26, 2026, at 8:30 a.m. Pacific Time, to solicit additional proxies for the Reverse Stock Split Proposal.
• A new record date of January 12, 2026, was set for the Reconvened Special Meeting.

Sentiment

Score: 3

Explanation: The company is taking extraordinary measures, including the issuance of a super-voting share to its CEO, to pass a reverse stock split. This indicates significant underlying issues, likely related to Nasdaq listing compliance, and a struggle to gain broad shareholder support. While a capital raise mechanism was approved, the governance implications of the super-voting share and the ongoing uncertainty surrounding the reverse split are significant negatives, pointing to a challenging operational and financial environment.

Positives

• The Stock Issuance Proposal and the Adjournment Proposal were approved by stockholders.
• Over 70% of the proxies received by the Company included instructions to vote FOR the Reverse Stock Split Proposal, indicating majority support among those who voted.

Negatives

• The Reverse Stock Split Proposal failed to secure the necessary two-thirds (2/3) of the voting power of outstanding shares, leading to multiple adjournments of the Special Meeting.
• The company resorted to creating and issuing a Super-Voting Share to its CEO to potentially ensure the approval of the Reverse Stock Split, which could be viewed as a measure to bypass broader shareholder consensus.

Risks

• Risk of not obtaining the requisite stockholder vote to approve the Reverse Stock Split.
• Risk of the Company's inability to timely regain compliance with Nasdaq listing rules if the Reverse Stock Split is not approved or effective.
• Potential negative outcomes for stockholders if the Reverse Stock Split Proposal is not approved by the stockholders at the Reconvened Special Meeting.
• General risks and uncertainties as detailed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The Company expects to reconvene its Special Meeting on January 26, 2026, to seek approval for the Reverse Stock Split Proposal. It will continue to solicit votes from stockholders, with the Super-Voting Share intended to enable approval if at least two-thirds of the common stock present and entitled to vote approve the proposal. The completion and effects of the Reverse Stock Split are subject to obtaining the requisite stockholder vote.

Management Comments

• The Board of Directors authorized the issuance of the Super-Voting Share to Jay M. Short, Ph.D.
• The Company encourages all stockholders who have not yet voted to do so promptly for the Reconvened Special Meeting.

Industry Context

Companies often pursue reverse stock splits to increase their share price and meet minimum listing requirements, such as Nasdaq's $1.00 bid price rule, or to enhance their appeal to institutional investors. The issuance of a super-voting share to a key executive to ensure the passage of such a critical proposal, particularly after multiple failed attempts to secure sufficient shareholder votes, is an aggressive corporate governance maneuver. This action suggests the company faces significant pressure to execute the reverse split, potentially to avoid delisting, and is struggling to achieve broad shareholder consensus through conventional means. This approach can raise concerns among investors regarding corporate governance practices and shareholder democracy.

Comparison to Industry Standards

• Issuing a super-voting share to a CEO to ensure a specific outcome on a shareholder vote, particularly for a reverse stock split, is an uncommon and aggressive corporate governance tactic. It deviates from standard practices where such proposals typically rely on the uncoerced majority vote of common shareholders.
• While reverse stock splits are a common tool for companies facing delisting threats due to low share prices (e.g., many small-cap biotech firms on Nasdaq), the method employed by BioAtla to secure approval, involving a specially created super-voting share, is not a standard industry approach and raises significant governance questions.
• Comparable situations where companies have struggled with shareholder approval for reverse splits often involve extensive proxy solicitations and engagement, but rarely the creation of a mechanism that effectively guarantees the outcome based on a specific threshold of *present* votes, rather than *outstanding* votes, for a single executive.

Corporate Governance

Related Party Transactions

• Issuance of one share of Series A Junior Preferred Stock to Jay M. Short, Ph.D., the Company's Chairman, Chief Executive Officer, and co-founder, for a purchase price of $0.01.

Stakeholder Impact

• Shareholders: Potential for dilution from the approved stock issuance. The Super-Voting Share could diminish the effective voting power of common shareholders on specific matters, raising concerns about shareholder democracy. There is a risk of delisting if the reverse stock split fails to pass or is not effective.
• Management/Board: The Super-Voting Share provides management with a mechanism to ensure the passage of critical corporate actions, such as a reverse stock split, which may be necessary for Nasdaq compliance, thereby strengthening the Board's ability to execute its strategic decisions.

Next Steps

• The Reconvened Special Meeting will be held virtually on January 26, 2026, at 8:30 a.m. Pacific Time, to vote on the Reverse Stock Split Proposal.
• The Company will continue to solicit votes from its stockholders with respect to the Reverse Stock Split Proposal.
• If approved, the Board may effect a reverse stock split at any time prior to June 30, 2026.

Key Dates

Recommendation

The company's actions, particularly the creation and issuance of a super-voting share to its CEO to force through a reverse stock split, signal significant underlying distress and a struggle to maintain Nasdaq listing compliance. This aggressive governance tactic, coupled with the repeated failure to secure sufficient shareholder votes, indicates a lack of broad investor confidence and raises serious concerns about shareholder democracy. Such measures often precede further negative developments or reflect a challenging operational environment, making the stock highly speculative and risky. Investors should consider exiting their positions due to these fundamental governance and operational red flags.

Keywords

BioAtla, BCAB, Reverse Stock Split, Super-Voting Share, Preferred Stock, Corporate Governance, Nasdaq Listing Rules, Shareholder Vote, Proxy Solicitation, Equity Issuance